Home » Stocks » SPHS

Sophiris Bio Inc. (SPHS)

Stock Price: $0.0143 USD 0.0043 (43.00%)
Updated Jul 30, 2021 3:58 PM EDT - Market closed
Market Cap 491,227
Revenue (ttm) n/a
Net Income (ttm) 37,000
Shares Out 34.47M
EPS (ttm) 0.00
PE Ratio 14.30
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $0.0143
Previous Close $0.0100
Change ($) 0.0043
Change (%) 43.00%
Day's Open 0.0129
Day's Range 0.0105 - 0.0160
Day's Volume 828,148
52-Week Range 0.0043 - 0.0700


SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), ...

1 year ago - GlobeNewsWire

About SPHS

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatm... [Read more...]

Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements